Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

NCT00973076 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Solid Tumors
Advanced Solid Malignancies

Interventions

DRUG: AZD8055

Sponsor

AstraZeneca